GLP-1s in Medicare and Medicaid: Access alone is not a care model
(Pankhuri Sharma, Humana for Becker’s Hospital Review) The clinical value of GLP-1 receptor agonists is now well established. Multiple trials
Read More(Pankhuri Sharma, Humana for Becker’s Hospital Review) The clinical value of GLP-1 receptor agonists is now well established. Multiple trials
Read More(Authors: Meredith Freed, Juliette Cubanski, and Elizabeth Williams for The Kaiser Family Foundation Published: May 11, 2026) GLP-1s, a class
Read More(By Jackie Fortiér for KFF Health News) Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription
Read More(By Juliette Cubanski for The Kaiser Family Foundation published March 9, 2026) The Centers for Medicare & Medicaid Services (CMS)
Read More(Contact – Craig Palosky for The Kaiser Family Foundation published November 14, 2025) About one in eight adults (12%) say
Read More(By: Paige Twenter for Becker’s Hospital Review) Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1
Read More(By: Erica Carbajal for Becker’s Hospital Review) CMS said April 4 it will not move forward with a Biden-era proposal
Read More(By Paige Twenter for Becker’s Hospital Review) On Dec. 23, the FDA approved Hikma Pharmaceuticals’ liraglutide injection, a generic version
Read More(By Alexandra Murphy for Becker’s Hospital Review) The FDA has updated the labels for all GLP-1 receptor agonists, including popular
Read More(By Elizabeth Williams, Robin Rudowitz, and Clea Bell for The Kaiser Family Foundation Published: Nov 04, 2024) GLP-1 (glucagon-like peptide-1)
Read More